22 Cherry Hill Drive
473 articles about Abiomed
Johnson & Johnson Completes Acquisition of Abiomed
Johnson & Johnson (NYSE: JNJ), the world’s largest, most diversified healthcare products company, today announced it has completed its acquisition of Abiomed, Inc.
FDA Approves Impella ECP Pivotal Heart Pump and First Patients Enrolled in Pivotal Clinical Trial
Abiomed (Nasdaq: ABMD) announces the United States Food and Drug Administration (FDA) has approved the version of Impella ECP that will be used in the Impella ECP Pivotal Trial, and the first two patients have been enrolled in the trial.
First Patients in the World Treated with Impella RP Flex with SmartAssist
Abiomed (Nasdaq: ABMD) announces the first three patients in the world have been treated with Impella RP Flex with SmartAssist, Abiomed’s newest heart pump for patients experiencing right heart failure.
Johnson & Johnson announced it was acquiring all outstanding shares of Abiomed for $16.6 billion to expand Abiomed's cardiovascular technologies and increase patient access.
Abiomed Announces Second Quarter Revenue of $266 Million, up 11% in Constant Currency*, up 7% on a Reported Basis Year Over Year
ABIOMED, Inc. today announces financial results for the quarter ended September 30, 2022.
Impella RP Flex with SmartAssist Receives FDA Approval to Treat Right Heart Failure
Abiomed (Nasdaq: ABMD) announces that Impella RP Flex with SmartAssist has received U.S. Food and Drug Administration (FDA) pre-market approval (PMA), the FDA’s highest level of approval, as safe and effective to treat acute right heart failure for up to 14 days.
Abiomed Creates Patient Assistance Program to Address Disparities in Healthcare
Abiomed announces a new program to address healthcare disparities in underserved communities, as new data provides an example of how better access to Impella heart pumps can improve health equity for non-Caucasian cardiovascular patients.
MedTechVets Appoints Patrice Sutherland, Enterprise Executive Director at Integra LifeScience, as New Board Chairperson
Patrice Sutherland, enterprise executive director at Integra Life Sciences, has been appointed Chairperson of the Board of Directors for MedTechVets, a nonprofit organization that helps military Veterans transition and gain employment at Medical Technology and Life Science companies.
Abiomed Successfully Completes All Impella Post-Approval Studies for High-Risk PCI, Cardiogenic Shock, Post-Cardiotomy Cardiogenic Shock and Right Heart Failure
Abiomed (Nasdaq: ABMD) announces the U.S. Food and Drug Administration (FDA) has accepted and closed the post-approval study reports related to the pre-market approvals (PMA) for Impella heart pumps.
Yale University Study Demonstrates Significant Survival Benefit in High-Risk PCI with Impella Support
An analysis of more than 2,000 patients from a large U.S. real-world database finds that patients who underwent a non-emergent high-risk PCI with the Impella heart pump had significantly improved survival, reduced myocardial infarction, reduced cardiogenic shock after PCI and shorter length of stay than matched patients treated with an intra-aortic balloon pump.
Abiomed Second Quarter Fiscal 2023 Earnings and Conference Call Notification
Abiomed, Inc . (NASDAQ: ABMD) announced that on Tuesday, November 1, 2022, the Company will release financial results for the second quarter of the fiscal year 2023.
Multi-Center, Multi-Society Study of Impella-supported Patients with Cardiogenic Shock due to Myocarditis in Japan Achieves 30-day Survival of 77%
Abiomed (ABMD) announces the result of a three-year, investigator-led study of all Impella-supported patients treated at 109 hospitals in Japan shows a 30-day survival rate of 77% for patients with cardiogenic shock due to myocarditis.
The FDA has a broad range of activities in the drug and medical device space. Here’s a look at the agency’s work this week.
FDA Approves RECOVER IV Randomized Controlled Trial with Exception from Informed Consent (EFIC)
Abiomed (Nasdaq: ABMD) announces two approvals from the U.S. Food and Drug Administration (FDA) related to clinical research of Impella heart pumps in acute myocardial infarction (AMI) cardiogenic shock patients.
TCT 2022: Impella Enables Complete Revascularization, Improved Quality of Life and Native Heart Recovery
Abiomed (Nasdaq: ABMD) will highlight how Impella heart pumps help heart teams achieve more complete high-risk revascularization and heart recovery in the catheterization lab and operating room at the Transcatheter Cardiovascular Therapeutics (TCT) 2022 Conference, held in Boston from September 16 to 19.
Restore EF Study Shows Heart Function, Symptom Improvements for High-Risk PCI Patients Supported by Impella
Abiomed (Nasdaq: ABMD) announces the results of the Restore EF study demonstrate Impella-supported high-risk percutaneous coronary intervention (PCI) leads to significant improvements in left ventricular ejection fraction (LVEF), angina symptoms and heart failure symptoms at follow-up.
ABIOMED Announces First Quarter Record Revenue of $277 Million, up 10% Year Over Year, up 12% in Constant Currency*
ABIOMED, Inc. (NASDAQ: ABMD), a leader in breakthrough heart, lung and kidney support technologies, today announces financial results for the quarter ended June 30, 2022.
Abiomed First Quarter Fiscal 2023 Earnings and Conference Call Notification
Abiomed, Inc . (NASDAQ: ABMD) announced that on Thursday, August 4, 2022, the Company will release financial results for the first quarter of the fiscal year 2023.
Abiomed to Host Investor Call on Heart Failure Opportunity With Impella 5.5 and Impella BTR Heart Pumps
Abiomed, Inc. (NASDAQ: ABMD) today announced that it will host an investor call on the heart failure opportunity with the Impella 5.5 and future Impella BTR heart pumps on June 24, 2022 from 2:30 p.m. – 3:30 p.m. ET.
Abiomed to Present (Live) at the William Blair 42nd Annual Growth Stock Conference
Abiomed to Present (Live) at the William Blair 42nd Annual Growth Stock Conference.